Cochin Cardiac Club

Health Blog by Dr.Uday Nair

MANAGEMENT OF PREGNANCY IN HEART VALVE REPLACEMENT PATIENTS.


Rheumatic heart disease is more common in developing countries like India, where it is estimated to occur at a rate of 1.62 per 1,000 in the general population and constitutes 40% to 50% of all cardiac diseases.As a result, a large number of young women have undergone valve replacement before they conceive.
Pregnancy is associated with a hypercoagulable state as a result of various physiologic and biochemical changes that take place during this period. For women with mechanical valve prostheses, there is a general acceptance worldwide that subcutaneous heparin be used during the 1st trimester of pregnancy and oral anticoagulants for the remaining period until about 2 to 3 weeks before the expected delivery date, when the patient is switched back to heparin. Various studies have demonstrated that such a regimen is not entirely safe owing to lack of compliance, which may in fact pose a considerable risk to the mother’s life.Some studies have also suggested that the risk of fetopathy associated with warfarin use in the 1st trimester is overstated.


Types of  Artificial Heart Valves


There are 2 types of prosthetic heart valves, bioprosthetic and mechanical. Although successful pregnancies are possible for women with prosthetic heart valves, there are potential complications—some of which can be fatal—for both types of valves.


Bioprosthetic Heart Valve


Women who have well-functioning bioprosthetic heart valves and who do not have other cardiac risk factors often have uncomplicated pregnancies. One advantage of bioprosthetic valves is that they are much less thrombogenic than mechanical valves; however, there is still a risk of thromboembolic complications. The main issues with bioprosthetic valves is their finite lifespan and their risk of structural valve deterioration (SVD).Serious SVD can require reoperation to replace the failing bioprosthetic valve.Overall, about 50% of women of childbearing age will       require valve replacement owing to SVD 10 years after the original operation; therefore, women of childbearing age who have bioprosthetic valves will likely require reoperation


Mechanical Heart Valve


Mechanical valves have excellent durability and SVD does not occur.In addition, newer-generation mechanical valves have superior hemodynamic profiles compared with stented bioprosthetic valves. All mechanical prosthetic valves, however, are thrombogenic and require lifelong anticoagulation to prevent thromboembolic complications.In addition, pregnancy is a hypercoagulable state. Examples of the types of thromboembolic complications that have        occurred during pregnancies associated with mechanical prosthetic valves include stroke, valve thrombosis, and myocardial infarction.Choosing which type of anticoagulation to use during pregnancy is problematic, as there is no perfect form available. Therefore, the major concerns associated with pregnant women with mechanical heart valves are thromboembolic complications (including fatal events), maternal bleeding, and increased fetal events.


Anticoagulation therapy
The types of anticoagulation that can be used during pregnancy include warfarin, unfractionated heparin, and low-molecular-weight heparin (LMWH)


Warfarin


Warfarin is the drug of choice in nonpregnant patients with mechanical heart valves and is highly effective in preventing thromboembolic complications. In pregnant women, it can cause a  specific embryopathy, consisting of nasal hypoplasia and epiphyseal stippling, albeit only when administered between 6 and 12 weeks of gestation.In a recent critical review of the available  published literature, the authors estimated that the true incidence of warfarin embryopathy with   exposure between 6 and 12 weeks of gestation was low( 5%); this contrasted with estimates of 30% or higher.Further, in recent follow-up studies of children born with warfarin embryopathy, major morbidity was uncommon, and many of these infants developed normally.
Other problems, such as fetal central nervous system abnormalities, have been reported in association with warfarin use at any stage of pregnancy.However, these events are rare and it is unclear whether the incidenceof any of these complications is higher than in pregnancies not associated with warfarin use. Finally, since warfarin crosses the placenta, maternal use can cause fetal hemorrhage, particularly during and immediately after delivery.However, this is likely to be rare and can be avoided by using a heparin (instead of warfarin) for the last part (2-4 weeks) of pregnancy.


Unfractionated Heparin


Since it does not cross the placenta, UFH is not teratogenic. However, multiple reports of thrombosed valves with the use of UFH,causing maternal morbidity and mortality, have raised seriousconcerns about its effectiveness.One plausible explanation for the failure of UFH is inadequate dosage. It is known that low-dose heparin(5000 IU every 8-12 hours subcutaneously) is inadequate for prevention of thrombosis of mechanical prosthetic heart valves during pregnancy; it is unclear whether 12-hourly subcutaneous UFH adjusted to prolong a midinterval activated partial thromboplastin time (aPTT) result to 1.5 to 2.5 times control is adequate. After initial heparin therapy, this regimen has been shown to be as effective as warfarin (with a target international normalized ratio [INR] of 2.0-3.0) for the prevention of recurrence in nonpregnant patients with acute venous thromboembolism.However, based on several considerations, this regimen of UFH might be less effective in pregnant women with mechanical heart valves. 
First, 1.5 times control, the usual lower limit of the therapeutic range, corresponds to subtherapeutic heparin levels (anti-factor Xa levels 0.3 U/mL)using most currently available a PTT reagents.
Second, except for patients who have bileaflet mechanical aortic valvesand do not have atrial fibrillation, the recommended target INR range for patients with mechanical heart valves (2.5-3.5) is higher than the corresponding target INR range for the treatment of acute venous thromboembolism (2.0-3.0), suggesting that more intense antithrombotic therapyis appropriate.Further, although warfarin, with a target INR of 2.0 to 3.0, is highly effective in the long-term treatment of acute venous thromboembolism, even with the use of a more intense warfarin regimen (INR of 2.5-3.5), theaddition of aspirin to the warfarin regimen improves efficacy for patients with mechanical heart valves (albeit at the cost of an increase in the rate of minor bleeding).Given this information, we recommend that if subcutaneous UFH is used to prevent thrombosis in pregnant women with mechanical heart valves, the starting dose should be high(17500-20000 U every 12 hours) and adjusted aggressively to achieve a mid-interval aPTT of at least 2.0 timescontrol or a result that corresponds to an anti-factor Xa heparin level of at least 0.3 to 0.5 U/mL. Finally, adjunctive aspirin therapy should be considered in high-risk women,such as those with previous systemic embolism and those with atrial fibrillation.The rate of major bleeding in pregnant patients treated with UFH has been reported to be approximately 2%, which is consistent with the reported rates of bleeding associated with heparin therapy in nonpregnant patients and with warfarin therapy when used for the treatment of deep vein thrombosis.Unfortunately,adjusted-dose subcutaneous UFH can cause a persistent anticoagulant effect at the time of delivery, which can complicate its use prior to labor.
Approximately 3% of nonpregnant patients receiving UFH develop immune, IgGme d i a t e d  t h r omb o c y t o p e n i a , wh i c h  i s  f r e q u e n t l y complicated by extension of preexisting venous throm-boembolism or new arterial thrombosis.In pregnant women, the true incidence of IgG-mediated thrombocytopenia is unknown. Long-term heparin therapy has been reported to cause osteoporosis in both laboratory animals and humans.Further, symptomatic vertebral fractures have been reported to occur in about 2% to 3% of patients receiving UFH for periods of 1 month or more and significant reductions in bone density have been reported in up to 30% of patients receiving long-term UFH.


Low-Molecular-Weight Heparin


The true incidence of valve thrombosis in enoxaparin- (orother LMWH-) treated pregnant women with mechanical heart valves and the optimal LMWH treatment regimen fortheir patients are unknown. Based on published data, there have been a small number of patients treated with LMWH,most successfully.The small numbers of patients withvalve thrombosis in the randomized trial of enoxaparin (2 of7, 29%) have very wide confidence intervals (4%-71%) and,when combined with the limitations of the postmarketingdata, preclude an accurate estimate of the true rate of fataland nonfatal valve thrombosis despite the information contained in the recent “Precaution” and “Dear Health CareProfessional” letter.The potential for teratogenicity of LMWHs lacks biologic plausibility because it has been demonstrated that these agents do not cross the placenta. In support of this,a recent comprehensive overview concluded that therewas no teratogenicity associated with LMWHs.



TREATMENT RECOMMENDATIONS


Women with mechanical heart valves should be carefully counseled about the risks associated with available anticoagulant options prior to, or shortly after, becoming pregnant. The practice of substituting warfarin with UFH or an LMWH between 6 and 12 weeks of gestation probably eliminates the risk of warfarin embryopathy (or other teratogenic effects) but might subject women to an increased risk of thromboembolism if inadequate dosesare used.One of the following approaches is recommended:
1. “Aggressive” adjusted-dose UFH throughout pregnancy; ie, administered subcutaneously every 12 hours in doses adjusted to maintain the mid-interval aPTT at a minimum of twice control or an anti-factor Xa heparin level of at least 0.3 U/mL.
2. Adjusted-dose LMWH throughout pregnancy; ie,administered subcutaneously every 12 hours in doses adjusted to maintain a 4- to 6-hour post injection antifactor Xa heparin level at a minimum of 0.5 U/mL.
3. UFH or LMWH (as above) until the 13th weekof pregnancy, then warfarin with a target INR of 2.5 to 3.5 until the middle of the third trimester, followed byreinitiation of UFH or LMWH until delivery.
With any of the 3 above regimens, adjunctive aspirin therapy should be considered. Long-term anticoagulants should be resumed post partum with all regimens


Prognosis


There have been several studies looking at the outcome of pregnancies in women with prosthetic heart valves.Women with mechanical valves have a higher complication rate, including the increase of both maternal and fetal events,compared with women with bioprostheses. Women with bioprostheses who are not using anticoagulation have been found to have excellent fetal outcomes.When compared with women with bioprosthetic valves, women with mechanical heart valves have a higher incidence of pregnancy loss, premature births, maternal deaths, thromboembolic complications, and bleeding.Women with bioprosthetic valves, however, have been found to have a higher incidence of structural valve failure, often occurring when both mothers and babies are still young.


Precaution


Women who have prosthetic heart valves and are of childbearing age should be counseled (ideally before conception) about the potential issues that might arise during pregnancy. Having a prosthetic heart valve puts both the mother and fetus at risk; therefore, management of these women is required throughout pregnancy in a specialized program for high-risk patients by a Cardiology team of doctors.



IRRITABLE BOWEL SYNDROME IN CHILDREN



Irritable bowel syndrome (IBS) is a chronic digestive condition. IBS affects people of all ages, including children. In children and adolescents, irritable bowel syndrome equally affects girls and boys.


Irritable bowel syndrome is classified as a functional disorder because it is caused by a problem in how the intestines (bowels) work. People, including children, with IBS tend to have overly sensitive intestines that go into muscle spasms in response to foods, gas, and sometimes stress. These spasms may cause pain, diarrhea, and constipation.


Between 5% to 20% of kids have IBS, and about 20% of adults do, too. It's not fun, but the good news is that IBS doesn't lead to more serious problems. It's irritating, but it can be managed and kids can do whatever activities they like in spite of it.

Symptoms


For children with irritable bowel syndrome, symptoms may include one or several of the following:
  • Abdominal (stomach) pain
  • Bloating
  • Gas
  • Changes in stool patterns, including diarrhea-predominant, constipation-predominant, or a variable stool pattern.
Causes 
Children with IBS may also have headaches, nausea, or mucus in the stool. Weight loss may occur if a child eats less to try to avoid pain. Some children first develop symptoms after a stressful event, such as teething, a bout with the flu, or problems at school or at home. Stress does not cause IBS, but it can trigger the symptoms.
No one really knows what causes IBS, although it tends to run in families.
Children with IBS can also have abnormalities in how their intestines contract, called motility, which refers to the rate stool moves through the intestines. Whereas a faster rate of movement may cause diarrhea, a slower rate may result in constipation.


Stress can affect kids with IBS, too. Stress can speed up your colon and slow your stomach down. Stressful feelings also can be a trigger for IBS. Let's say a kid has a big test at school the next day and really worries about it, that's stress. Or if a kid sees his or her parents fighting and begins to feel worried — that's stress, too. A kid in this situation can learn to handle stress in other ways, so IBS symptoms will go away or at least be less severe.
What kids eat can also be a trigger, but this can be different for each kid. For example, a high-fat diet may bother some kids. Drinks high in sugar may cause diarrhea in other kids. Eating big meals and spicy foods often cause problems, so if you have IBS, try to avoid those.
Diagnosis
IBS can cause recurring abdominal pain in children. Your child may be diagnosed with IBS if she suffers from abdominal pain plus any two of the following:
  • Bowel movement relieves the pain.
  • Onset of pain is associated with a change in stool frequency.
  • Onset of pain is associated with a change in consistency of stool.
Symptoms present for at least 12 weeks of the preceding 12 months are considered indicative of IBS. Additionally, doctors will rule out any diseases that might cause the same symptoms.
To make a diagnosis of IBS, the doctor asks questions about symptoms and examines the child to rule out more serious problems or diseases. IBS is not a disease, but a syndrome, which just means a group of symptoms that occur together. It doesn't damage the intestine, and in children IBS is treated mainly through changes in diet.
Treatment

In severe cases, the doctor might give a person some medicine for IBS to reduce pain, as well as help manage gas, constipation, diarrhea, and the need to rush to the bathroom.
The best solution, however, is for a kid to learn what makes the symptoms worse and avoid whatever it is.with his or her parents.
Although each person's food triggers may be a little different, here are some common ones:
  • big meals
  • spicy foods
  • high-fat foods
  • chocolate
  • some dairy products like ice cream or cheese
It's not just what a person eats — what he or she doesn't eat also may lead to IBS symptoms. Fruits, vegetables, and high-fiber foods like beans and popcorn can help keep a kid's colon running properly. Your doctor might recommend a fiber supplement as well. Drinking water can help a cranky colon, too.
Please Note
The IBS symptoms with children can fluctuate as they grow older. However it is usually present for the at least the initial 5 years when inflicted with this condition and the severity levels may vary between various children.
It is more likely for children to have IBS in high school than they would in middle school. It is equally likely for IBS to affect boys versus girls. 
When a child has IBS, it is important to provide them with the attention that they require. It is a very troublesome condition even in adults so think about having a younger aged individual having to deal with this.Ensure that the children are candid about their symptoms with you and that they fully express their feelings with you. This way you can provide them with the help that they require, whether it would be through daily chores such as cooking meals, cleaning, etc. It is important to provide them with sufficient time to cope with this condition when they are first diagnosed with this condition.

WHAT ARE PROBIOTICS?



Bacteria have a reputation for causing disease, so the idea of tossing down a few billion a day for your health might seem — literally and figuratively — hard to swallow. But a growing body of scientific evidence suggests that you can treat and even prevent some illnesses with foods and supplements containing certain kinds of live bacteria. 




Probiotics are dietary additions that contain useful bacteria or yeast. These bacteria can confer health benefits if consumed in the right quantities. In India, probiotics have mostly found their way into curd and ice-creams.Probiotic curds in India are marketed by Amul, Nestle and Mother Dairy.


USES:



  • Probiotics comprise of over four hundred different types of bacteria which are beneficial for the gastrointestinal system as they enhance digestive functions. They help reduce the symptoms associated with acid reflux which include heartburns, nausea and regurgitation, by improving digestive functions.
  • The best case for probiotic therapy has been in the treatment of diarrhea. Controlled trials have shown that Lactobacillus GG can shorten the course of infectious diarrhea in infants and children (but not adults).
  • Probiotic therapy may also help people with Crohn’s disease and irritable bowel syndrome.
  • Probiotics may also be of use in maintaining urogenital health. Like the intestinal tract, the vagina is a finely balanced ecosystem. The dominant Lactobacilli strains normally make it too acidic for harmful microorganisms to survive. But the system can be thrown out of balance by a number of factors, including antibiotics, spermicides, and birth control pills. Probiotic treatment that restores the balance of microflora may be helpful for such common female urogenital problems as bacterial vaginosis, yeast infection, and urinary tract infection.
Probiotics and Safety?
Most probiotics are sold as dietary supplements, which do not undergo the testing and approval process that drugs do. Manufacturers are responsible for making sure they’re safe before they’re marketed and that any claims made on the label are true. But there’s no guarantee that the types of bacteria listed on a label are effective for the condition you’re taking them for. Health benefits are strain-specific, and not all strains are necessarily useful, so you may want to consult a practitioner familiar with probiotics to discuss your options. As always, let your primary care provider know what you’re doing.

  • Probiotics can no longer be considered harmless and should not be given to severely ill patients with organ failure, those on a feeding tube or in intensive care.
  • It is also noted that the “good bacteria” commonly found in probiotic yogurt (commonly known as curd in India) and drinks can be fatal for people suffering from severe pancreatitis.


Few Brands available in India?




Ecoflora Capsules marketed by Tablets India Ltd.
Ecoflora & other brands naturally restore disturbed vaginal ecology in a number of vaginal infections involving bacteria , yeast & other pathogens. Ecoflora is the first orally administered uro-genital probiotic that descends the GI-tract & ascends the female genital tract.


Probiotics with ORS
Biors Sachets marketed by Tablets India Ltd.


BIFILAC Capsules / Sachets marketed by Tablets India Ltd.
( Combination of functional pre-biotics with a probiotic )


ViBact Capsules / Sachets marketed by USV

 Binifit Capsules / Sachets marketed by Ranbaxy


 Becelac PB Capsules marketed by Dr. Reddy's Labs


 Vizyl Capsules / Sachets marketed by Unichem



Gutpro Capsules / Sachets marketed by JBCPL


Please Note:


Some people may experience mild stomach upset, diarrhea or flatulence during the first few days of probiotic supplementation. Further, some people may be allergic to or intolerant of certain probiotic supplements, or to the probiotic food in which they are presented. However, in most cases, probiotic food is well tolerated, and at the very least, may provide one with better intestinal health.